[{"Month":"October 2024","NewsReleases":[{"Title":"AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024","Date":"10.15.2024","Url":"/newsroom/press-releases/2024/10/amgen-presents-positive-phase-3-data-for-uplizna-inebilizumabcdon-in-generalized-myasthenia-gravis-gmg-at-aanem-2024"},{"Title":"LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFE","Date":"10.01.2024","Url":"/newsroom/press-releases/2024/10/la-la-anthony-partners-with-amgen-to-share-candid-behindthescenes-look-at-how-plaque-psoriasis-affects-her-life"}]},{"Month":"September 2024","NewsReleases":[{"Title":"TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE","Date":"09.24.2024","Url":"/newsroom/press-releases/2024/09/tepezza-teprotumumab-receives-approval-in-japan-for-the-treatment-of-active-thyroid-eye-disease"},{"Title":"AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE","Date":"09.23.2024","Url":"/newsroom/press-releases/2024/09/amgen-to-host-conference-call-to-discuss-new-topline-data-in-inflammation-and-rare-disease"},{"Title":"AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024","Date":"09.13.2024","Url":"/newsroom/press-releases/2024/09/amgen-to-present-data-from-multiple-early-stage-clinical-trials-at-esmo-2024"}]}]